OrbiMed raises $3 billion, its biggest Asian fund yet, to boost biotech investments worldwide

OrbiMed announced it has closed a $3 billion fundraising round, the largest ever for its Asia‑focused vehicle. The capital will be used to make new growth‑equity and venture investments in biotech and life‑science companies across the United States, Europe and Asia.

The latest fund, OrbiMed Asia Partners VI, secured more than $1 billion, up from $751 million in the previous iteration and $800 million in the fourth fund. The increase reflects growing investor appetite for Asian life‑science opportunities, a trend echoed by TCGX’s recent $600 million Asia fund.

OrbiMed’s portfolio now lists 22 Asian biopharma companies, and managing partner Carl Gordon highlighted China’s rise as a biotechnology powerhouse as a key driver of the firm’s confidence in the region’s pipeline potential.